Outpatient Oncology Infusion Market Report 2026

The outpatient oncology infusion market size has grown strongly in recent years. It will grow from $14.02 billion in 2025 to $15.12 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing cancer prevalence rates, expansion of outpatient oncology infrastructure, adoption of infusion-based therapies, improved survival rates requiring ongoing treatment, availability of advanced infusion devices.

The outpatient oncology infusion market size is expected to see strong growth in the next few years. It will grow to $20.21 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing demand for precision oncology treatments, rising investments in outpatient infusion centers, expansion of home-compatible infusion technologies, growing focus on cost-efficient cancer care, increasing integration of digital oncology monitoring. Major trends in the forecast period include increasing shift toward outpatient cancer treatment models, rising adoption of targeted and immunotherapies, growing use of smart infusion pumps, expansion of ambulatory infusion centers, enhanced focus on patient-centric oncology care.

The growing prevalence of cancer cases is expected to drive the growth of the outpatient oncology infusion market in the coming years. Cancer is a group of complex diseases characterized by the uncontrolled growth of abnormal cells, which can invade surrounding tissues and metastasize to other parts of the body. The increase in cancer cases is largely due to aging populations worldwide, as the risk of developing cancer rises significantly with age. Outpatient oncology infusion provides cancer treatments such as chemotherapy, immunotherapy, or targeted therapy in a clinical setting without requiring hospital admission, allowing patients to receive care while maintaining their daily routines. For example, in April 2024, according to Macmillan Cancer Support, a UK-based charity offering practical, emotional, and financial support to people affected by cancer, the number of individuals living with cancer in the UK is projected to exceed 3 million presently, reaching 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the rising prevalence of cancer cases is fueling the growth of the outpatient oncology infusion market.

Leading companies in the outpatient oncology infusion market are focusing on technological advancements in infusion systems, such as next-generation smart infusion pumps, to improve medication safety and streamline chemotherapy delivery. Next-generation smart infusion pumps are digitally connected devices equipped with advanced dose-error reduction software, integrated drug libraries, and real-time connectivity to minimize errors and standardize oncology treatments. For instance, in April 2024, Baxter International Inc., a US-based medical technology company, received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Novum IQ large-volume infusion pump, making it available for U.S. ordering. The integrated hardware-software system delivers precise large-volume infusions with embedded safety checks, dose-library enforcement, and connectivity for remote management. Baxter emphasizes its advanced safety architecture, improved usability, and compatibility with its broader infusion ecosystem. The pump is suitable for outpatient oncology infusion centers, ambulatory clinics, and hospitals, offering benefits such as enhanced dosing accuracy, streamlined nursing workflows, and reduced delays or adverse events during chemotherapy administration.

In December 2024, Cardinal Health, a US-based healthcare products, services, and distribution company, acquired Integrated Oncology Network (ION) for an undisclosed amount. Through this acquisition, Cardinal Health aims to expand its specialty-care presence by integrating ION’s more than 50 community-based oncology and urology practice sites across 10 U.S. states into its oncology alliance network, enhancing service offerings, broadening provider reach, and strengthening value-based care delivery across the cancer care continuum. Integrated Oncology Network is a US-based healthcare network that provides a full spectrum of oncology and urology care, including medical oncology, radiation oncology, diagnostic testing, surgical oncology, and ancillary services, through its community-based practice sites.

Major companies operating in the outpatient oncology infusion market are Medtronic plc, Becton Dickinson and Company, Baxter International Inc., Fresenius Kabi AG, Terumo Corporation, Nipro Corporation, Smiths Medical Inc., ICU Medical Inc., B. Braun Melsungen AG, InfuSystem Holdings Inc., BPL Medical Technologies Private Limited, Angiplast Private Limited, Bio-Med Healthcare Products Private Limited, Lars Medicare Private Limited, Micrel Medical Devices S.A., AKAS Infusions Private Limited, Mais India Medical Devices Private Limited, Wellead Medical Co. Ltd., AdvaCare Pharma USA LLC, Polymed Medical Devices Private Limited.

North America was the largest region in the outpatient oncology infusion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the outpatient oncology infusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the outpatient oncology infusion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the outpatient oncology infusion market by increasing costs of imported infusion pumps, intravenous consumables, oncology-grade medical devices, and digital monitoring systems. Oncology centers in North America and Europe are most impacted due to reliance on imported infusion technologies and specialized consumables, while Asia-Pacific faces elevated equipment procurement costs. These tariffs are increasing treatment delivery costs and slowing infrastructure expansion. However, they are also encouraging domestic production of infusion devices, localized supply chains, and innovation in cost-optimized oncology treatment solutions.

The outpatient oncology infusion market research report is one of a series of new reports that provides outpatient oncology infusion market statistics, including outpatient oncology infusion industry global market size, regional shares, competitors with a outpatient oncology infusion market share, detailed outpatient oncology infusion market segments, market trends and opportunities, and any further data you may need to thrive in the outpatient oncology infusion industry. This outpatient oncology infusion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Outpatient oncology infusion refers to the administration of cancer-fighting medications to patients in non-hospital settings, such as infusion centers or clinics. This approach provides effective, convenient, and cost-efficient cancer treatment while allowing patients to avoid extended hospital stays.

The primary product types of outpatient oncology infusion include infusion pumps, intravenous sets, intravenous cannulas, and needleless connectors. Infusion pumps are medical devices that deliver controlled amounts of fluids, such as medications or nutrients, into a patient’s body over a specified period. These devices support therapies including chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. They are applied across cancer types such as lung, liver, breast, and prostate cancers, and are utilized by end users including hospitals, outpatient clinics, and home care settings.

The outpatient oncology infusion market consists of revenues earned by entities by providing services such as hormone therapy infusions, supportive care infusions, patient monitoring, patient education, and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The outpatient oncology infusion market also includes sales of biosimilars, immunotherapy agents, supportive care drugs, infusion bags, IV poles, and stands. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.